Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain;Estudio coste-efectividad del uso de dosis altas de atorvastatina en la prevención secundaria del ictus en España

Revista de Neurologia

Volumn 51, Issue 1, 2010, Pages 1-11

  Arrospide Elgarresta, Arantzazu ^a   Mar, Javier ^a   Vivancos Mora, José ^b   Rejas Gutiérrez, Javier ^c   Caro, Jaime ^d,e  

^a Hospital Alto Deba   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c PFIZER INC   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Atorvastatin; Cardiovascular risk; Cerebrovascular disease; Cost effectiveness; Statins; Stroke; Transient ischemic attack

Indexed keywords

ATORVASTATIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SIMULATION; SPAIN; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL TIME; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 77954411471     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5101.2009604     Document Type: Article

References (47)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
2. Banegas JR, Rodríguez-Artalejo F. Epidemiología del ictus en España y factores de riesgo relacionados. Hipertensión 2005; 22 (Supl 3): S5-13.
3. Fernández de Bobadilla J, Sicras-Mainar A, Navarro-Artieda R, Planas-Comes A, Soto-Álvarez J, Sánchez-Maestre C, et al. Estimación de la prevalencia, incidencia, comorbilidades y costes directos asociados en pacientes que demandan atención por ictus en un ámbito poblacional español. Rev Neurol 2008; 46: 397-405.
4. Carod-Artal FJ, Egido-Navarro JA, González-Gutiérrez JL, Varela de Seijas E. Coste directo de la enfermedad cerebrovascular en el primer año de seguimiento. Rev Neurol 1999; 28: 1123-30.
5. Arrazola A, Begiristain JM, Mar J. Atención hospitalaria a la enfermedad cerebrovascular aguda y situación de los pacientes a los 12 meses. Rev Neurol 2005; 40: 326-30.
6. Mar J, Sainz-Ezkerra M, Moler-Cuiral JA. Calculation of prevalence estimates through differential equations: application to stroke-related disability. Neuroepidemiology 2008; 31: 57-66. (Pubitemid 351957399)
7. Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence through Markov models. Application to prevalence-based economic evaluation of thrombolysis for stroke. Med Decis Making 2008; 28: 481-90.
8. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
9. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009; 169: 260-8.
10. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
11. Kent DM. Stroke -an equal opportunity for the initiation of statin therapy. N Engl J Med 2006; 355: 613-5.
12. Commission on Macroeconomics and Health (2001). Report of the Commission on Macroeconomics and Health -Macroeconomics and health: investing in health for economic development Geneva: World Health Organization. URL: http://www3.who.int/whosis/cmh/cmh-report/report.cfm?path=whosis,cmh, cmh-report&language=english. [19.12.2006].
13. Rubio S. Estudios de farmacoeconomía a través de modelos basados en el análisis de decisión. In Domínguez-Gil A, Soto J, eds. Farmacoeconomía e investigación de resultados en salud: principios y práctica. 3 ed. Madrid: Real Academia Nacional de Farmacia; 2002. p. 263-5.
14. Rodríguez Barrios JM. El papel de los modelos en la evaluación económica en el campo sanitario. Farm Hosp 2004; 28: 31-242.
15. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4: 348-61.
16. Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, Le-Lorier J, Ouellette P, et al. Pharmacoeconomics and health policy. Current applications and prospects for the future. Pharmacoeconomics 1999; 16: 425-32.
17. Chang K, Nash D. The role of pharmacoeconomic evaluations in disease management. Pharmacoeconomics 1998; 14: 11-7. (Pubitemid 28332694)
18. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modelling Studies. Value Health 2003; 6: 9-17.
19. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004.
20. Kongnakom T, Ward A, Roberts CS, O'Brien JA, Proskorovsky I, Caro JJ. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health 2009; [Epub ahead of print].
21. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology 2003; 228: 659-68.
22. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23: 323-32.
23. Cooper K, Davies R, Roderick P, Chase D, Raftery J. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002; 5: 259-67.
24. Babad H, Sanderson C, Naidoo B, White I, Wang D. The development of a simulation model of primary prevention strategies for coronary heart disease. Health Care Manag Sci 2002; 5: 269-74.
25. Bozzette SA, Boer R, Bhatnagar V, Brower JL, Keeler EB, Morton SC, et al. A model for a smallpox-vaccination policy. N Engl J Med 2003; 348: 416-25.
26. Davies R, Roderick P, Canning C, Brailsford S. The evaluation of screening policies for diabetic retinopathy using simulation. Diabet Med 2002; 19: 762-70.
27. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in athero thrombosis. Value Health 2004; 7: 627-35.
28. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in patients at risk of ischaemic events. Am J Med 1999; 107: 568-72.
29. Kelton WD, Sadowski RP, Sturrock DT. Simulation with ARENA. New York: McGraw-Hill; 2007.
30. Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scott Med J 1957; 2: 200-15.
31. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999; 52: 259-71. (Pubitemid 29148438)
32. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083-91.
33. Franks P, Hanmer J, Fryback D. Relative disutilities of 27 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample. Med Care 2006; 44: 478-85.
34. Catálogo de Especialidades Farmacéuticas de 2008. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos de España; 2008.
35. Gisbert R, Brosa M. Base de datos de costes sanitarios eSALUD. URL: http://www.oblikue.com/bddcostes. [02.02.2009].
36. Mar J, Begiristain, JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005; 20: 193-200.
37. Briggs AH, Goeree R, Blackhouse G, O'Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002: 22: 290-308.
38. Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001; 357: 1612-6.
39. Banegas JR, Rodríguez-Artalejo F, Graciani A, Villar F, Herruzo R. Mortality attributable to cardiovascular risk factors in Spain. Eur J Clin Nutr 2003; 57 (Suppl 1): S18-21.
40. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002; 4: 334-43.
41. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin 2008; 24: 1217-29.
42. Doggrell SA. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Rev Recent Clin Trials 2006; 1: 143-53.
43. Sanossian N, Ovbiagele B. Drug insight: translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol 2008; 4: 43-9.
44. Fernández de Bobadilla J, Moreno R, Fernández C, Martínez A, Sánchez-Maestre C, Ezpeleta-Echevarri D. Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes. Rev Neurol 2009; 48: 561-5.
45. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-54.
46. Hilden J. Budget impact analysis and its rational basis. Med Decis Making 2008; 28: 461-2.
47. Mortimer D, Segal L, Sturm J. Can we derive an 'exchange rate' between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) technique. Health Qual Life Outcomes 2009, 7: 33.